Interaction of 5′-Guanosine Monophosphate with Organotin(IV) Moieties: Synthesis, Structural Characterization, and Anti-Inflammatory Activity

Table 3

Anti-inflammatory activity and toxicity data of di- and triorganotin(IV) derivatives of (5′-GMP)²⁻.

Complex/standard drug	Anti-inflammatory activity^a		Toxicity LD50
	Dose (mg/kg p.o.)	% inhibition	mg/kg p.o.
[Me2Sn(5′-GMP)·H2O]𝑛	40	18.12	>400
[n-Bu2Sn(5′-GMP)·H2O]𝑛	40	16.32	>400
[Ph2Sn(5′-GMP)·H2O]𝑛	40	19.22	>400
[(i-Pr3Sn)2(5′-GMP)·H2O]𝑛	40	15.64	>400
[(n-Bu3Sn)2(5′-GMP)·H2O]𝑛	40	17.34	>400
[(Ph3Sn)2(5′-GMP)·H2O]𝑛	40	20.63	>400
Phenyl butazone	40	34.56	>2000

^a% inhibition in paw edema = [(DC−DT)/DC]×100, where DT and DC are the mean volumes of paw edema in drug-treated and control groups. Standard deviation (𝜎) in DC is <0.09 and in DT <0.15.
Standard error in mean [(SEM)=(𝜎/(𝑁)^1/2)] in DC is <0.040 and in DT <0.067.